Back to search results
NCT06235567

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

Enrolling by Invitation
PHASE1Ages 13–64InterventionalTreatment
Maanasa Indaram, MD
~20 participants
Updated 2026-03-24 on ClinicalTrials.gov
What's tested:Dextenza 0.4Mg Ophthalmic Inserttopical prednisolone acetate 1% (PredForte) eye drops

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Corneal haze
Measured over 1 months (30 days)
+3 more outcomes measured

Conditions

Keratoconus

Explore related trials

Keratoconus

Where it's being run

3 sites across 1 states
California3

Study leadership

  • Maanasa Indaram, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

History of acute hydrops in treated eye
History of pre-existing severe corneal scarring in the treated eye
History of pre-existing glaucoma in the treated eye
History of or pharmaceutical treatment of glaucoma or ocular hypertension and history or current spikes in intraocular pressure (IOP) in either eye.
History of pre-existing ocular inflammation or infection (conjunctivitis, keratitis, uveitis, or retinitis) in treated eye
Active infectious systemic disease
Obstructed nasolacrimal duct in the study eye(s)
Patients with a nasolacrimal duct smaller than 0.4 mm or greater than or equal to 1.0 mm.
Patients with stenosis to the location where the insert will be placed should be excluded from the study, as the study team would not engage in surgical procedures to expand or surgically correct that region
Hypersensitivity to dexamethasone
Patients being treated with immunomodulating agents in the study eye(s)
Patients being treated with immunosuppressants and/or oral steroids
Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

What this trial measures

  • Corneal haze1 months (30 days)

    Assess the efficacy of the dexamethasone insert compared to corticosteroid drops for post-treatment in patients who have had epithelium-off corneal collagen cross linking procedure. This will be assessed by -Postoperative corneal haze as measured by the Physician with a slit lamp biomicroscopy and graded on a scale of 0-4+ (0 = least haze ; 4= most haze)

  • Corneal re-epithelialization6 months (180 days)

    Assess the efficacy of the dexamethasone insert compared to corticosteroid drops for post-treatment in patients who have had epithelium-off corneal collagen cross linking procedure. This will be assessed by -Physician measured corneal re-epithelialization after bandage contact lens removal by slit lamp biomicroscopy.

  • Keratometry6 months (180 days)

    Assess the efficacy of the dexamethasone insert compared to corticosteroid drops for post-treatment in patients who have had epithelium-off corneal collagen cross linking procedure. This will be assessed by Postoperative keratometry values (diopters) as measured by corneal topography or Pentacam tomography. Comparing the pre- to post- operative values.

  • Infection6 months (180 days)

    Adverse event end point: Postoperative infection as measured at any visit.